


# Study Results Keynote-426

A study of pembrolizumab plus axitinib versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma


source : ASCO GU 2019, <https://meetinglibrary.asco.org/record/170343/abstract>



**861**  
Patients




**129**  
Trial Sites




**16**  
Countries

## Trial Design



## Objective Response Rate (ORR)

in the whole trial population (regardless of IMDC categories)



**59.3% vs 35.7%**

% of Patients with Partial or Complete Response

## Progression Free Survival (Median PFS)




**15.1 Months**




**11.1 Months**

## Complete Response (CR)




**5.8%**




**1.9%**

## Overall Survival (OS) 12-month rate



**89.9%**



**78.3%**

## Treatment-related Side Effects All Patients

Grade 3 - 5



**63.8%\***



**59.7%\***



\* Including Grade 5 (death related to treatment) for 0.9% and 1.6% respectively)

© IKCC = International Kidney Cancer Coalition, [www.ikcc.org](http://www.ikcc.org), [www.10forio.info](http://www.10forio.info)

